News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Retroscreen Virology Limited To Present Research On Quigley Corporation's (QGLY) QR-435 At The VI International Symposium On Respiratory Viral Infections

10/19/2005 5:10:02 PM

DOYLESTOWN, Pa.--(BUSINESS WIRE)--Feb. 17, 2004--The Quigley Corporation (Nasdaq: QGLY - News) reported today that Retroscreen Virology Ltd., under the auspices of Professor John S. Oxford, will be presenting the results of their recent research on Quigley's patented formulation and its activity against both the Influenza A and SARS viruses at the VI International Symposium on Respiratory Viral Infections between March 18 - 21, 2004 at the Sanibel Harbour Resort & Spa, Fort Myers, Florida, USA.

Retroscreen, a world leading independent contract research virology company, specializes in developing anti-viral compounds and vaccines. Retroscreen has worked with many large pharmaceutical companies to assist them in developing products that now help to fight viral diseases worldwide.

The influenza study found that intranasal application by spray of Quigley Pharma's QR-435 was 100 percent effective in preventing non-infected ferrets in close proximity to an infected ferret from becoming infected with the influenza A virus. The ferret is an established animal model for the study of influenza infection. On the strength of this data, Quigley intends to initiate a Phase II proof of concept human trial in Europe.

In a second experiment, in-vitro, Retroscreen Virology Ltd demonstrated that the compound showed significant virucidal activity against the Urbani strain of the Severe Acute Respiratory Syndrome (SARS) virus.

About Retroscreen Virology Limited

Retroscreen Virology Limited is an independent research virology company affiliated with the University of London. Professor John S. Oxford, the firm's senior scientist, is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. Dr. Oxford is the co-author of two standard texts on influenza and virology and has published more than 250 scientific papers throughout the world. Retroscreen specializes in developing anti-viral compounds and vaccines, and has worked with many pharmaceutical companies to assist them in developing products that now help to fight viral disease worldwide. Additional information is available on the company's website at

About Quigley

The Quigley Corporation (Nasdaq: QGLY - News),, is a leading developer and marketer of diversified health products including the Cold-EezeĀ® family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free tablets. Cold-Eeze is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the company has formed Quigley Pharma Inc. ( ), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean that the formula test compound, referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well controlled clinical studies before the clinical significance of the formula test compound is known.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.


Lippert Heilshorn & Associates David K. Waldman/John J. Quirk, 212/838-3777 or

The Quigley Corporation Carl Fonash, 267/880-1111

Source: The Quigley Corporation

Read at

comments powered by Disqus